Kadmon, A Sanofi Company
Biotechnology, 450 E 29th St, New York, 10016, United States, 51-200 Employees
Phone Number: 83********
Who is KADMON, A SANOFI COMPANY
Kadmon, a Sanofi Company, is a biopharmaceutical company that discovers, develops and markets transformative therapies for unmet medical needs. Our team has a proven track record of succe...
Read More
-
Headquarters: 450 E 29th St, New York, New York, 10016, United States
-
Employees: 51-200
-
Revenue: $50 Million to $100 Million
Industry: Biotechnology
SIC Code: 2834
|
NAICS Code: 621999 |
Show More
Does something look wrong? Fix it. | View contact records from KADMON, A SANOFI COMPANY
Kadmon, a Sanofi Company Org Chart and Mapping
Email
Phone
Sign in to CIENCE GO Data to uncover contact details
Free credits every month
Frequently Asked Questions Regarding Kadmon, a Sanofi Company
Answer: Kadmon, a Sanofi Company's headquarters are located at 450 E 29th St, New York, 10016, United States
Answer: Kadmon, a Sanofi Company's phone number is 83********
Answer: Kadmon, a Sanofi Company's official website is https://kadmon.com
Answer: Kadmon, a Sanofi Company's revenue is $50 Million to $100 Million
Answer: Kadmon, a Sanofi Company's SIC: 2834
Answer: Kadmon, a Sanofi Company's NAICS: 621999
Answer: Kadmon, a Sanofi Company has 51-200 employees
Answer: Kadmon, a Sanofi Company is in Biotechnology
Answer: Kadmon, a Sanofi Company contact info: Phone number: 83******** Website: https://kadmon.com
Answer: Kadmon, a Sanofi Company, is a biopharmaceutical company that discovers, develops and markets transformative therapies for unmet medical needs. Our team has a proven track record of successful drug development and commercialization. Our clinical pipeline includes treatments for immune and fibrotic diseases as well as immuno-oncology therapies. Our late-stage product candidate, belumosudil, is an orally administered selective inhibitor of Rho-associated coiled-coil kinase 2 (ROCK2) in development for the treatment of inflammatory and fibrotic diseases. A pivotal study of belumosudil is underway in chronic graft-versus-host disease (cGVHD), as well as a Phase 2 study in systemic sclerosis. Kadmon is also developing next-generation immuno-oncology therapies, specifically IL-15 containing fusion proteins, for the treatment of cancer. Our lead I-O product candidate, KD033, is an anti-PD-L1/IL-15 fusion protein in a Phase 1 clinical trial. Comments are no longer monitored.
Premium Sales Data for Prospecting
-
Sales data across over 200M records
-
Up-to-date records (less decayed data)
-
Accurate Email Lists (real-world tested)
-
Powerful search engine and intuitive interface
Get Full Access
Sign in to CIENCE GO Data to uncover contact details
Free credits every month